ANL - adlainortye.com Company Cash Funds

Corporate emblem and logo of Adlai Nortye (ANL)

Adlai Nortye Ltd. plans to generate revenue through the implementation of palifermine therapy for tumor treatment in China and the US. Development is proceeding via international scientific partnerships without capital mergers. On GURU.Markets, the free cash flow level demonstrates financial autonomy, where the 0.23 metric determines this level. This helps assess the strategy for capturing the biopharma market through the development of targeted molecules and the drug buparlisib.

Company Cash Balance: Adlai Nortye (ANL) for 02/21/2024 - 11/21/2026

Summary analytical data breakdowns for Adlai Nortye Ltd. (ANL)

- stock value and consensus price forecast:
Analysis of all company metrics:Adlai Nortye Ltd. ANL
Product sample of Adlai Nortye Limited

For the biopharmaceutical business of Adlai Nortye Ltd. (ANL), which focuses on high-cost oncology research, analyzing the cash on hand allows for an assessment of the funding stability for clinical trials. This indicator captures the actual balance of highly liquid assets, measuring the company's ability to cover operating expenses without external borrowing, where the balance between reserves and investments determines the pace of new drug development.

Direct competitors

Company Cash Volume ONC|HALO - Company Cash Reserve|Revolution Medicines - Company Cash on Hand|Company Cash Volume Ascentage Pharma AAPG|CGON - Company Cash Funds|Company Total Cash Volume URGN|BCAX: Company Cash Volume|PSNL - Company Liquid Assets|ERAS (Erasca Inc) - Company Cash Volume|Company Cash Reserve Delcath Systems Inc DCTH|Company Cash Funds YmAbs (YMAB)|Company Liquid Assets Aura Bio|Company Cash Volume CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Company Cash Reserve|SELLAS Life Sciences Group - Company Cash Volume|ACTU - Company Cash Volume|CTOR: Company Cash Volume|Company Cash Reserve TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Company Cash Volume|Fate Therapeutics, Inc. (FATE) - Company Liquid Assets|Company Cash on Hand WHWK (Aadi Bioscience, Inc.)|Company Liquid Assets TScan Therapeutics, Inc.|Company Cash Volume CSBR (Champions Oncology Corp)|Company Total Cash Amount XBIT (XBiotech USA)|CVM - Company Cash Funds|Company Cash Balance OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Company Cash Funds|ARTV: Company Total Cash Amount|Company Cash on Hand VERU|Tempest Therapeutics (TPST) - Company Liquid Assets|Company Cash Volume XLO|Company Cash on Hand Renovaro RENB|Company Cash Volume MURA (Mural Oncology PLC)|KAPA - Company Cash on Hand|OnKure Therapeutics - Company Cash Volume|w2.cytomed.sg - Company Total Cash Amount|Curis Corp (CRIS) - Company Cash Funds|Company Cash Reserve Apollomics Corp (APLM)|Company Cash Funds Tharimmune|Company Cash Volume advanbiomed.com|Company Cash Funds Genprex, Inc (GNPX)|Company Liquid Assets Calidi Biotherapeutics, Inc.|Company Cash Volume SBFM (Sunshine Biopharma Inc.)|XBIO - Company Cash on Hand|SLRX: Company Cash on Hand|Company Cash Balance PPBT (Purple Biotech Ltd.)|AONC: Company Cash Volume|Company Cash Reserve BeOne Medicines (BGNE)|Company Cash Funds Checkpoint Therapeutics, Inc.|Company Cash on Hand Elevation Oncology (ELEV)|Company Cash Funds iCAD Corp (ICAD)|Company Cash on Hand Ikena IKNA|Company Cash Volume NTBL (notablelabs.com)|VIRX - Company Cash on Hand|MOR: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds